Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Ergun Y., Esen S. A., Bardakci M., Ucar G., Kalkan Z., Urakci Z., ...Daha Fazla

CANCER BIOMARKERS, cilt.34, sa.2, ss.329-336, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3233/cbm-210455
  • Dergi Adı: CANCER BIOMARKERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.329-336
  • Anahtar Kelimeler: Immune checkpoint inhibitor, nivolumab, ABO blood group, predictive, biomarker, TUMOR-NECROSIS-FACTOR, CANCER RISK, SURVIVAL, ASSOCIATION
  • Gazi Üniversitesi Adresli: Evet

Özet

BACKGROUND: The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now.